Skip to main content
padlock icon - secure page this page is secure

Evaluation of the Test-Retest Model of Anxiety in Mice

Buy Article:

$68.00 + tax (Refund Policy)

A test-retest protocol of an animal model of anxiety induces an increase of anxious behaviour and a loss of benzodiazepine induced effect. This effect mainly observed in the elevated plus maze, an ethological model of anxiety in mice, but also in the four plate test, a model based on punishment, was called the one trial tolerance. In the first step, a review of some hypotheses based on behavioural, pharmacological and neurochemical approaches is proposed to explain this benzodiazepines tolerance phenomenon on a test-retest model of anxiety, namely the four-plate test. Aversive memory consists of a diminution of the number of accepted punished passages. “One trial tolerance” is the abolishment of the anxiolytic-like effect of a drug in experimented mice. Diazepam, a usual benzodiazepine affected by one trial tolerance, is used in parallel with DOI, a 5-HT2A agonist that keeps its anxiolytic-like effect during retest, in order to study this phenomenon. Local injection of DOI and diazepam revealed that hippocampus was activated by DOI. Diazepam was active when injected into lateral nuclei of amygdala in naive mice, and into periaqueductal gray matter in experiment mice.

These results suggest that aversive memory and one trial tolerance seem triggered via different mechanisms, supported by different structures.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Amygdala; Benzodiazepines (BZD); GABAA; Intra peritoneally; Periaqueductal gray; Periaqueductal gray matter; Test-retest; anxiety models; barbiturates; chlordiazepoxide; diazepam; four-plate test; hippocampus; one trial tolerance

Document Type: Research Article

Publication date: August 1, 2012

More about this publication?
  • Current Psychopharmacology publishes peer-reviewed expert review articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology. Data must be published for the first time in Current Psychopharmacology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more